Immunocore Holdings plc (IMCR) stock
IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3017% below fair value
$26.41−0.22 (-0.83%)
Close on Nov 20, 2026Market cap $1.36BP/E –Yield 0.00%
Immunocore free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Immunocore's free cash flow for the twelve months ending Jun 30, 2026 was -$41.15M, down 244.6% year over year. For fiscal 2025 it was -$15.05M, down 172.1% from the year before. The highest annual figure on record is $20.89M in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$15.05M | -172.1% |
| FY2024 | Dec 31, 2024 | $20.89M | – |
| FY2023 | Dec 31, 2023 | -$2.49M | – |
| FY2022 | Dec 31, 2022 | -$51.41M | – |
| FY2021 | Dec 31, 2021 | -$144.49M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $15.14M | -40.7% |
| Q1 FY2026 | Mar 31, 2026 | -$15.56M | -11454.7% |
| Q4 FY2025 | Dec 31, 2025 | -$35.54M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.20M | -125.6% |
| Q2 FY2025 | Jun 30, 2025 | $25.55M | +10.4% |
| Q1 FY2025 | Mar 31, 2025 | $137.00K | – |
| Q4 FY2024 | Dec 31, 2024 | -$17.54M | – |
| Q3 FY2024 | Sep 30, 2024 | $20.30M | +105.5% |
| Q2 FY2024 | Jun 30, 2024 | $23.14M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.02M | -166.6% |
| Q4 FY2023 | Dec 31, 2023 | -$18.55M | – |
| Q3 FY2023 | Sep 30, 2023 | $9.88M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.35M | – |
| Q1 FY2023 | Mar 31, 2023 | $7.54M | – |
See a number that looks wrong?